SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention after a sharp breakout to a 52-week high, with traders focused on heavy call buying and positioning ahead of the Q3 report. Buyout and short-squeeze theories are circulating, but remain speculation; others point to BRIUMVIs sales growth as the underlying driver.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA submission for sonelokimab in hidradenitis suppurativa has put FDA acceptance and the review timeline at the center of discussion. Traders are split between optimism about the drugs potential and a possible partnership or acquisition, and concerns about regulatory risk, competition, and the cost of commercializing it independently.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,811.032761 with 281,866,747.320393 in circulation. The last known price of OFFICIAL TRUMP is 1.57555883 USD and is down -1.93 over the last 24 hours. It is currently trading on 744 active market(s) with $126,884,732.61 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

The Trump-themed meme coin is drawing attention amid its steep decline from earlier highs, with many traders calling it a pump-and-dump and pointing to losses among holders. A smaller bullish contingent sees the recent price strength as accumulation or a possible squeeze, while election-related speculation adds to the debate over demand.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP-linked ETF attention centers on reported fund inflows and optimism around regulatory clarity, with some traders viewing institutional demand as supportive while others question whether it has translated into price gains. Discussion also reflects confusion between the XRP token and Bitwises ETF, alongside concern about weakness in the broader crypto market.

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,022,365,191.094644 with 95,022,375,662.737444 in circulation. The last known price of TRON is 0.30232528 USD and is down -8.04 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,465,217,312.79 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRON is drawing attention for its steady price action, with traders debating whether consolidation and technical support point to further gains or continued stagnation. Some bullish posts also cite the networks stablecoin-transfer activity, while others remain frustrated by the coins slow performance.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Roots Hyundai Secure+ partnership is drawing attention after the product was identified as powered by Root, with traders focused on its potential to expand embedded, dealership-based insurance sales. Bulls see Hyundai and Kias vehicle sales as a significant distribution opportunity, while skeptics question how quickly the rollout can translate into policy growth amid recent concerns about declining policies in force.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owls Q3 results beat expectations, and traders are highlighting growth in assets under management, fee-related earnings, and managements outlook for future fee growth and dividend coverage. Bulls see room for a valuation recovery, while skeptics remain focused on private-credit redemption concerns and put-heavy options activity.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results are driving the sharp rally, with traders highlighting growth in Dupixent and Eylea HD and the stocks breakout to a new high. The reaction is broadly bullish, though some note that declining legacy Eylea sales and biosimilar competition remain risks.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirms strong quarterly results and better-than-expected outlook, followed by analyst upgrades, have driven attention. Traders are split after the initial earnings rally reversed sharply: some see profit-taking despite solid growth, while others point to a one-time tax benefit, elevated valuation, and rate and consumer-credit concerns.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is drawing attention after a sharp move higher as traders seek leveraged protection against Nasdaq weakness. Bearish views focus on concerns that heavy AI spending may not deliver returns and on broader tech-market volatility, while others expect a rebound and warn that the ETFs daily leverage makes it risky to hold long term.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NTLA The hype of 2021 turns into reality... Invivo Gene editing... Theory in 2021 turned into reality 5 years later... While the price went from hype to pessimism... We are on our way from bottom back to real value... Better step in at the bottom before the crowd jumps into the bandwagon... Early bird get fattest worm... 😎😎😎

Maximus

matty

Jimmy Aaron

Robbie

Canucks48

StockTwits For Android 

Intellia Therapeutics Inc

 The hype of 2021 turns into reality... Invivo Gene editing... Theory in 2021 turned into reality 5 years later... While the price went from hype to pessimism... We are on our way from bottom back to real value... Better step in at the bottom before the crowd jumps into the bandwagon... Early bird get fattest worm... 😎😎😎

Ferdinand Baudet

@GoodTidings no deal signed yet in Iran, maybe still pick up some NTLA at a good price (but it probably rockets higher in the pre-market). Maybe up a couple bucks instead of ten bucks

StockTwits Web

 no deal signed yet in Iran, maybe still pick up some NTLA at a good price (but it probably rockets higher in the pre-market). Maybe up a couple bucks instead of ten bucks